Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; National Consumer Surveys on Understanding the Risks and Benefits of FDA-Regulated Medical Products
Health and Human Services Department; Food and Drug Administration · 2011
Read Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; National Consumer Surveys on Understanding the Risks and Benefits of FDA-Regulated Medical Products by Health and Human Services Department; Food and Drug Administration (2011) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/uslaw-fr-2011-16251.txt.
Description
Notice published in the Federal Register on 2011-06-29 by Health and Human Services Department; Food and Drug Administration. Text from federalregister.gov (official edition: govinfo). [Pages 38186-38187] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 2011-16251] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2010-N-0502] Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; National Consumer Surveys.
Catalog record
| CREATOR | Health and Human Services Department; Food and Drug Administration |
|---|---|
| YEAR | 2011 |
| COLLECTION | LAW |
| FORMAT | TXT |
| FILE SIZE | 8 KB |
| VERSION | 1.0 |
| LICENSE | Public Domain |
| RIGHTS | PUBLIC DOMAIN |
| SOURCE | Federal Register |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; National Consumer Surveys on Understanding the Risks and Benefits of FDA-Regulated Medical Products
Citation: us:fr:2011-16251
Creator: Health and Human Services Department; Food and Drug Administration
Year: 2011
Source-URL: https://www.federalregister.gov/documents/2011/06/29/2011-16251/agency-information-collection-activities-submission-for-office-of-management-and-budget-review
Context: Notice published in the Federal Register on 2011-06-29 by Health and Human Services Department; Food and Drug Administration. Text from federalregister.gov (official edition: govinfo).
[Pages 38186-38187]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2011-16251]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-N-0502]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; National Consumer
Surveys on Understanding the Risks and Benefits of FDA--Regulated
Medical Products
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995.
DATES: Fax written comments on the collection of information by July
29, 2011.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
Fax: 202-395-7285, or e-mailed to [email protected]. All
comments should be identified with the OMB control number 0910-New and
title ``National Consumer Surveys on Understanding the Risks and
Benefits of FDA-Regulated Medical Products.'' Also include the FDA
docket number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Jonna Capezzuto, Office of Information
Management, Food and Drug Administration, 1350 Piccard Dr., PI50-400B,
Rockville, MD 20850, 301-796-3794. [email protected].
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
National Consumer Surveys on Understanding the Risks and Benefits of
FDA-Regulated Medical Products--(OMB Control Number 0910-NEW)
Risks and benefits are inherent in all FDA-regulated medical
products, including drugs, biologics, and medical devices (e.g.,
pacemakers, implantable cardiac defibrillators, contact lenses,
infusion pumps). FDA plays a critical oversight role in managing and
preventing injuries and deaths related to medical product use. However,
the users of FDA-regulated products are ultimately the ones who
determine which products are used and how they are potentially misused.
For this reason, it is critical that the public understand the risks
and benefits of FDA-regulated medical products to a degree that allows
them to make rational decisions about product use.
FDA's responsibility includes communicating about medical products.
This encompasses communications that FDA generates and those it
oversees through regulation of product manufacturers' and distributors'
communications. Activities include, but are not limited to, recall
notices, warnings, public health advisories and notifications, press
releases, and information made available on its Web site. FDA also
regulates communications drafted and disseminated by manufacturers and
distributors of many medical products, including all the communications
(advertising and labeling) about prescription drugs, biologics, and
restricted medical devices, and a subset of communications (omitting
advertising) about nonprescription drugs and other medical devices. In
order to conduct educational and public information programs relating
to these responsibilities, as authorized by section 1003(d)(2)(D) of
the Federal Food Drug and Cosmetic Act (21 U.S.C. 393(d)(2)(D)), it is
beneficial for FDA to conduct research and studies relating to health
information as authorized by section 1701(a)(4) of the Public Health
Service Act (42 U.S.C. 300u(a)(4)).
In conducting such research, FDA will employ nationally
representative surveys of consumers to assess whether the information
being disseminated by both the Agency and the entities it regulates is
appropriately reaching targeted audiences in an understandable fashion.
Specifically, the surveys will assess public understanding about the
benefits and risks of medical products and FDA's role in regulating
these products. The surveys will assess behaviors and beliefs related
to the use of medical products, when consumers desire emerging risk
information, the likelihood of reporting serious side effects that
might be associated with medical product use, perceptions of the
credibility of FDA and other potential sources of risk and benefit
information, and satisfaction with FDA's communications-related
performance.
Parallel surveys of 1,500 noninstitutionalized U.S. adults will be
administered. One survey of 1,500 subjects will be a telephone survey,
and the second survey of another 1,500 subjects will be conducted with
members from an Internet panel. Both survey samples will be constructed
to be representative of the U.S. population, and both will take
approximately 15 minutes to administer. Results from each survey will
be compared to provide insight into the best methodology for future
studies.
The information collected will be used by FDA in the development of
more effective risk communication strategies and messages. The surveys
will provide FDA insight as to how well the public understands and
incorporates risk/benefit information into their belief structures, and
how well the public understands the context within which FDA makes
decisions on medical product recalls and warnings. Using this
information, the Agency will more effectively design messages and
select formats and distribution channels that have the greatest
potential to influence the target audience's attitudes and behavior in
a favorable way. Frequency of Response: On occasion. Affected Public:
Individuals or households; Type of Respondents: Members of the public.
In the Federal Register of October 5, 2010 (75 FR 61490), FDA
published a 60-day notice requesting public comment on the proposed
collection of
[[Page 38187]]
information. No comments were received.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden \1\
----------------------------------------------------------------------------------------------------------------
Number of
Type of respondent Number of responses per Total annual Average burden Total hours
respondents respondent responses per response
----------------------------------------------------------------------------------------------------------------
Pretests........................ 30 1 30 0.25 (15 min.) 8
Screener........................ 6,700 1 6,700 0.10 (6 min.) 670
Telephone survey................ 1,500 1 1,500 0.25 (15 min.) 375
Internet panel survey........... 1,500 1 1,500 0.25 (15 min.) 375
-------------------------------------------------------------------------------
Total....................... .............. .............. .............. .............. 1,428
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
Dated: June 23, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011-16251 Filed 6-28-11; 8:45 am]